Exagen Inc. revised revenue guidance for the first quarter of 2023. The company provided first quarter of 2023 revenue guidance of $8.2 million to $9.2 million. The strong momentum seen in fourth quarter of 2022 have continued and the company increasing revenue guidance to a range of $9.2 million to $9.7 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.05 USD | -5.09% | +10.22% | +3.02% |
May. 14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
May. 13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.02% | 35.62M | |
+19.32% | 84.59B | |
-21.99% | 77.33B | |
+0.70% | 27.12B | |
-5.06% | 18.19B | |
+7.87% | 18.49B | |
+7.69% | 16.49B | |
+76.20% | 13.55B | |
+76.56% | 13.03B | |
-27.54% | 12.43B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Revises Revenue Guidance For the First Quarter of 2023